Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, announced that abstracts from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and the OV101 (gaboxadol) clinical development program in Angelman syndrome (Phase 2 STARS study), will be presented at the American Epilepsy Society (AES) 2020 Virtual Congress, taking place December 4-8, 2020.
“There remains significant unmet medical needs for the treatment of Dravet, Lennox-Gastaut, and Angelman syndromes, all of which are neurological conditions with highly impactful effects on individuals, caregivers, and their families,” said Amit Rakhit, MD, MBA, President and Chief Medical Officer at Ovid. “It is important that we continue to analyze data from studies like ELEKTRA and STARS, as we advance understanding of these conditions and work towards our goal of addressing demonstrated gaps in treatment.”
Details of the presentations are as follows:
Title: Efficacy, safety, and tolerability of soticlestat (TAK-935/OV935) as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA); Hahn, et al.
Poster Number: #851
Title: Quantitative analysis of EEG signals in STARS, a Phase 2 safety, tolerability, and exploratory efficacy study of gaboxadol in adolescents and adults with Angelman syndrome; Wang, et al.
Poster Number: #49
To register for this event, click here.